Enzymatica AB Share Price

Equities

ENZY

SE0003943620

Pharmaceuticals

Market Closed - Nasdaq Stockholm 16:29:38 15/05/2024 BST 5-day change 1st Jan Change
3.2 SEK -1.54% Intraday chart for Enzymatica AB +2.56% -18.88%

Financials

Sales 2024 * 6M 63.9M 473M Sales 2025 * 11.54M 123M 911M Capitalization 51.93M 554M 4.1B
Net income 2024 * -4M -42.63M -316M Net income 2025 * -1M -10.66M -78.9M EV / Sales 2024 * 9.07 x
Net Debt 2024 * 2.46M 26.23M 194M Net cash position 2025 * 1.65M 17.55M 130M EV / Sales 2025 * 4.36 x
P/E ratio 2024 *
-12.5 x
P/E ratio 2025 *
-21.4 x
Employees 16
Yield 2024 *
-
Yield 2025 *
-
Free-Float 39.33%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.54%
1 week+2.56%
Current month+5.61%
1 month-11.60%
3 months-1.39%
6 months-5.47%
Current year-18.88%
More quotes
1 week
2.75
Extreme 2.75
3.33
1 month
2.75
Extreme 2.75
3.59
Current year
2.31
Extreme 2.305
4.10
1 year
2.10
Extreme 2.1
4.43
3 years
2.10
Extreme 2.1
13.40
5 years
2.00
Extreme 2
24.70
10 years
1.82
Extreme 1.815
24.70
More quotes
Managers TitleAgeSince
Founder 59 31/12/06
Chief Executive Officer 63 17/07/17
Director of Finance/CFO 55 31/12/17
Members of the board TitleAgeSince
Chairman 62 18/12/16
Director/Board Member 56 14/02/16
Director/Board Member 57 30/04/21
More insiders
Date Price Change Volume
15/05/24 3.2 -1.54% 63,370
14/05/24 3.25 +3.17% 95,036
13/05/24 3.15 +0.32% 49,176
10/05/24 3.14 +0.64% 83,579
08/05/24 3.12 -3.70% 90,279

Delayed Quote Nasdaq Stockholm, May 15, 2024 at 04:29 pm

More quotes
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise